495 filings
144
VKTX
Viking Therapeutics Inc
3 May 24
Notice of proposed sale of securities
4:04pm
4
Marianna Mancini
2 May 24
Viking Therapeutics / Marianna Mancini ownership change
9:27pm
144
Marianna Mancini
1 May 24
Notice of proposed sale of securities
4:02pm
10-Q
2024 Q1
VKTX
Viking Therapeutics Inc
Quarterly report
24 Apr 24
8:42pm
8-K
VKTX
Viking Therapeutics Inc
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
ARS
8h6ly0m 45b0yz
5 Apr 24
Annual report to shareholders
4:15pm
DEFA14A
o4b62m1o qfcs2d0
5 Apr 24
Additional proxy soliciting materials
4:10pm
4
65ybof202th uf94
27 Mar 24
Viking Therapeutics / Marianna Mancini ownership change
8:52pm
4
1t3tcu
27 Mar 24
Viking Therapeutics / Brian Lian ownership change
8:51pm
4
7qdn675eto5h
27 Mar 24
Viking Therapeutics / GREG ZANTE ownership change
8:50pm
8-K
fsoh8ji yp
26 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:08am
4
qdb8h 3kd
4 Mar 24
Viking Therapeutics / Brian Lian ownership change
7:54pm
4
q03qr 88r
4 Mar 24
Viking Therapeutics / Marianna Mancini ownership change
7:52pm
4
fx5fetj
4 Mar 24
Viking Therapeutics / GREG ZANTE ownership change
7:50pm
8-K
v4cwt7r2q36p7941d0c4
4 Mar 24
Other Events
4:52pm
424B5
bapkpdpq0l1y 1sq
1 Mar 24
Prospectus supplement for primary offering
4:13pm
8-K
0uttg
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
424B5
pqxfx9h d8hf3
27 Feb 24
Prospectus supplement for primary offering
5:21pm
8-K
jj7tqe0337gy6i
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am